View Item 

Show simple item record

Mini‐HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?
dc.contributor.authorMarini, Bernard L.
dc.contributor.authorPerissinotti, Anthony J.
dc.contributor.authorBixby, Dale L.
dc.contributor.authorBurke, Patrick W.
dc.contributor.authorPettit, Kristen M.
dc.contributor.authorBenitez, Lydia L.
dc.date.accessioned2019-10-30T15:30:07Z
dc.date.availableWITHHELD_14_MONTHS
dc.date.available2019-10-30T15:30:07Z
dc.date.issued2019-11-01
dc.identifier.citationMarini, Bernard L.; Perissinotti, Anthony J.; Bixby, Dale L.; Burke, Patrick W.; Pettit, Kristen M.; Benitez, Lydia L. (2019). "Mini‐HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?." Cancer (21): 3890-3891.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/151845
dc.publisherIBM Corporation
dc.publisherWiley Periodicals, Inc.
dc.titleMini‐HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151845/1/cncr32381_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/151845/2/cncr32381.pdf
dc.identifier.doi10.1002/cncr.32381
dc.identifier.sourceCancer
dc.identifier.citedreferenceJabbour EJ, Sasaki K, Ravandi F, et al. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome–negative acute lymphoblastic leukemia: a propensity score analysis [published online April 15, 2019]. Cancer. doi: 10.1002/cncr.32139
dc.identifier.citedreferenceThomson Reuters. IBM Micromedex: RED BOOK Drug References. Armonk, NY: IBM Corporation; 2019.
dc.identifier.citedreferenceGokbuget N, Dombret H, Giebel S, et al. Minimal residual disease level predicts outcome in adults with Ph‐negative B‐precursor acute lymphoblastic leukemia. Hematology. 2019; 24: 337 ‐ 348.
dc.identifier.citedreferenceMace M, Savoy JM, Rausch CR, et al. HOPA 2019 abstracts. Efficacy and tolerability of age‐adjusted hyperCVAD in older patients with newly diagnosed acute lymphoblastic leukemia. J Oncol Pharm Pract. 2019; 25 ( suppl 3 ): 1 ‐ 24.
dc.identifier.citedreferenceRibera JM, Garcia O, Oriol A, et al; PETHEMA Group, Spanish Society of Hematology. Feasibility and results of subtype‐oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016; 41: 12 ‐ 20.
dc.identifier.citedreferenceGeyer MB, Hsu M, Devlin SM, Tallman MS, Douer D, Park JH. Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood. 2017; 129: 1878 ‐ 1881.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32381_am.pdf
Size:
108.8KB
Format:
PDF
View/Open
Name:
cncr32381.pdf
Size:
82.14KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.